Advr Advanced Viral Research Corp.
ADVR bullish engulfing candle. Could be bounce time..
PROFILE
Advanced Viral Research Corp. (OTCBB: ADVR) is a biopharmaceutical company committed to researching, developing and bringing to market new therapies for viral and other diseases. Founded in 1984, the Company has headquarters in Yonkers, New York. The 17,650 square foot facility also includes research laboratory facilities, quality control/quality assurance laboratories, and a production facility designed to produce AVR118 to cGMP standards.
back to top
KEY PRODUCT
Advanced Viral’s principal pharmaceutical product, AVR118, represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers, and the body wasting (cachexia) that is a frequent complication of cancers and AIDS.
back to top
SIZE OF KEY POTENTIAL MARKETS
• AIDS “Salvage” Therapy - The Centers for Disease Control and Prevention (CDC) estimate a prevalence of 850,000 to 950,000 patients in the U.S. with HIV infection. The CDC further estimate that approximately 40,000 persons are newly infected with HIV each year in the U.S. and that there were 15,245 AIDS related deaths in the U.S. in 2000. The National Institutes of Health (NIH) estimates that 40 million people worldwide were living with HIV/AIDS at the end of 2001.
• Solid Tumors - The American Cancer Society estimates that female breast, colorectal, lung and bronchus, prostate and urinary bladder cancers will account for a total of 766,700 new cases of solid tumors and 281,300 deaths in the U.S. in the year 2002.
•Leukemia/Lymphomas - The American Cancer Society estimates that 60,900 new cases of lymphoma will occur in the U.S. in the year 2002, comprising 7,000 cases of Hodgkin's disease and 53,900 cases of non-Hodgkin's lymphoma. These cancers are estimated to cause a total of 25,800 deaths in the U.S. in the year 2002. It is estimated that 30,800 new cases of leukemia will occur in the U.S. in 2002 and that 21,700 patients will die with leukemia in 2002.
• Genital Warts (HPV infection) – The CDC currently reports an estimated 5.5 Million new cases of HPV each year and an estimated 20 million people in the U.S. are currently infected. Certain strains of HPV cause cervical dysplasia and cervical cancer.
back to top
AVR118 PATENTS
ADVR holds a patent on the preparation of a therapeutic composition of AVR118, and has nine other patents related to AVR118. The Company also has applications for approximately 20 additional patents related to AVR118, and continues to submit applications for additional patents as appropriate.
back to top
CLINICAL TRIALS
• AVR118 is the subject of Phase I/II clinical trials at the Chaim Sheba Medical Center, Israel, in patients who have failed highly active anti-retroviral therapy (HAART) treatment and require salvage therapy.
BOARD OF DIRECTORS
The ADVR Board of Directors are: Eli Wilner, Chairman; Dr. Elma S. Hawkins, Ph.D., MBA, CEO; Charles H. Moore, Executive Director of the Committee to Encourage Corporate Philanthropy (CECP); Nancy J. Van Sant, Esq., Director with Sacher, Zelman, Van Sant, Paul, Beiley, Haltman & Waldman, P.A.; Roy S. Walzer , founder, private investment firm Litchfield Partners, Ltd. and Litchfield Partners I.
back to top
SCIENCE ADVISORY BOARD
The ADVR Science Advisory Board includes: Dr. George Canellos (Harvard Medical School and Dana Farber Cancer Institute); Dr. James D’Olimpio (North Shore University Hospital and NYU School of Medicine); Dr. Michael Harris (Tomorrow's Children’s Institute for Cancer and Blood Disorders and UMDNJ-New Jersey Medical School); and Dr. Sidney Pestka (Professor and Chairman of the Department of Molecular Genetics, Microbiology and Immunology at Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey and is chairman and chief scientific officer of PBL Biomedical Laboratories, Piscataway, New Jersey)
|
Linear Mode
